News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

17th Oct 19

Pharmaxis Receives $6.2m R&D Tax Incentive as it Advances Drug Candidates into Clinical Development

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) has received a $6.2 million R&D tax incentive in relation to the 2019 financial year. The receipt of this incentive adds to the Company’s cash funds, which were $31 million at 30 June 2019.

The 2019 incentive effectively reduces Pharmaxis 2019 expenditure on research and development by more than 40%.

Pharmaxis CEO Gary Phillips said, “The R&D tax incentive provides significant leverage to the Pharmaxis research team’s development of new drugs for inflammation and fibrotic diseases. The Pharmaxis research team has taken four in-house compounds to Phase 1 trials in just five years and in the 2019 year alone completed phase 1 trials in two LOXL2 inhibitors, commenced phase 1 trials in a systemic LOX inhibitor compound and advanced a topical LOX inhibitor through preclinical development.”

Read full media release - pdf
12th Sep 19

Pharmaxis Recognised as a Top Innovator Company in Asia Pacific

Pharmaceutical research company Pharmaxis (ASX: PXS) has welcomed its inclusion in a new report which ranks the company among the top 100 most innovative pharma companies in the APAC region.

The report prepared by Cortellis and entitled “Pharmaceutical innovation in the APAC region”, studied a cohort of 929 companies (including multi-nationals) across 14 countries/regions that have or are developing innovative pharmaceutical products.

Pharmaxis was ranked 38 out of the 100 companies named as innovators in the small to medium- sized enterprises category. Amongst the 14 Australian companies included in the top 100, Pharmaxis was ranked second.

The Cortellis Report can be downloaded at: http://discover.clarivate.com/APAC_PharmaRanking

Read full media release - pdf
20th Jun 19

Pathway to US Approval Clarified After FDA Issues Complete Response Letter on Use of Bronchitol for Adult CF Patients - NDA Expected to be Completed Q1 2020

Pharmaceutical company Pharmaxis (ASX: PXS) today announced its US licensee Chiesi Group (Chiesi) has received a complete response letter from the US Food and Drug Administration (FDA) detailing the remaining matters to be addressed before Bronchitol® can be approved for adult cystic fibrosis (CF) patients in the United States. Based upon the clear and achievable path to approval communicated in the FDA complete response letter, Pharmaxis believes that the FDA review of the Bronchitol NDA will be completed in Q1 2020.

Read full media release - pdf